Cardiology
Metabolic Syndrome
More in Metabolic Syndrome
But GI side effects higher than other comparable anti-obesity agents
Recent developments of interest in cardiovascular medicine
Another study showed two high doses were better at reducing HbA1c vs a 14-mg dose
Plus, two other studies on retatrutide show benefit in type 2 diabetes, fatty liver disease
Daily orforglipron also lowered HbA1c in type 2 diabetes
Recent developments of interest in cardiovascular medicine
Survivors on aromatase inhibitors lost significantly less weight
Recent developments of interest in cardiovascular medicine
Recent developments of interest in cardiovascular medicine
Recent developments of interest in cardiovascular medicine
Patients had lower odds of lipid, cardio, or diabetes drug prescriptions for up to 15 years
Recent developments of interest in cardiovascular medicine
Overall, nearly half dropped below threshold for obesity
Recent developments of interest in cardiovascular medicine
